Dizal to Present Novel Cancer Therapies DZD8586 and DZD6008 at ASCO 2025
核心洞察
Dizal (搜索)'s first-in-class LYN (搜索)/BTK (搜索) dual inhibitor DZD8586 will be featured in oral and poster presentations for chronic lymphocytic leukemia (搜索) and diffuse large B-cell lymphoma (搜索) at ASCO 2025.
DZD6008, a highly selective EGFR (搜索) TKI with full blood-brain barrier penetration, will showcase clinical data for EGFR-mutated non-small cell lung cancer (搜索) patients who have failed third-generation EGFR TKI therapy.
Both investigational drugs address significant unmet needs: DZD8586 targets both BTK (搜索)-dependent and independent resistance mechanisms in B-cell lymphomas, while DZD6008 offers potential treatment for NSCLC patients with brain metastases (搜索).
Dizal (搜索) Pharmaceutical (SSE:688192) announced that its investigational drug candidates DZD8586 and DZD6008 have been selected for presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30-June 3 in Chicago.
The Shanghai-based biopharmaceutical company will showcase oral and poster presentations of DZD8586 study results in chronic lymphocytic leukemia (搜索) (CLL) and diffuse large B-cell lymphoma (搜索) (DLBCL). Additionally, clinical data for DZD6008, a fourth-generation EGFR (搜索) tyrosine kinase inhibitor (TKI), in non-small cell lung cancer (搜索) (NSCLC) will be presented during the conference.
DZD8586: Addressing Dual Resistance Mechanisms in B-cell Lymphomas
DZD8586 represents a significant advancement as a first-in-class, non-covalent LYN (搜索)/BTK (搜索) dual inhibitor with full blood-brain barrier (BBB) penetration. The drug was specifically designed to overcome limitations in current B-cell non-Hodgkin lymphoma (搜索) (B-NHL) treatments.
While Bruton's Tyrosine Kinase (BTK (搜索)) inhibitors have improved outcomes for B-NHL patients, resistance remains a critical challenge through two primary mechanisms: BTK C481X mutations and BTK-independent BCR signaling pathway activation. Currently, no targeted therapy effectively addresses both resistance mechanisms simultaneously.
Dr. Xiaolin Zhang, Chief Scientific Officer at Dizal (搜索), explained the drug's unique mechanism: "By targeting both BTK (搜索) and LYN (搜索) kinases, DZD8586 blocks both BTK-dependent and independent BCR-signaling pathways, effectively inhibiting tumor growth in preclinical models."
Phase I clinical trial data suggests DZD8586 exhibits favorable pharmacokinetic properties, good central nervous system penetration, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in B-NHL patients.
DZD6008: Novel Solution for EGFR-Mutated NSCLC with Brain Metastases
DZD6008, Dizal (搜索)'s novel EGFR (搜索) TKI, addresses a significant unmet need in advanced EGFR mutation-positive (EGFRm) NSCLC, particularly for patients with brain metastases (搜索) who have progressed on third-generation EGFR TKIs.
Brain metastases (搜索) represent a leading cause of death and disease progression in NSCLC patients. Approximately 23-30% of NSCLC patients present with synchronous brain metastases at initial diagnosis, and studies report that the 3-year cumulative rate of brain metastases ranges from 29.4% to 60.3% in patients with EGFR (搜索) mutations.
"The clinical benefits of existing treatments for third-generation EGFR (搜索) TKI-resistant NSCLC are limited," said Dr. Wei Li, Chief Medical Officer at Dizal (搜索). "DZD6008 is specifically designed to address this gap with its high selectivity and full blood-brain barrier penetration."
Previous clinical studies have validated DZD6008's design concept, demonstrating good safety and efficacy in NSCLC patients with brain metastases (搜索) who had failed third-generation EGFR (搜索) TKI therapy or multiple lines of pre-treatments.
Expanding Dizal's Oncology Portfolio
These presentations at ASCO 2025 highlight Dizal (搜索)'s growing presence in oncology drug development. The company has established an internationally competitive portfolio with two leading assets in global pivotal studies, both of which have already been launched in China.
"Our focus on translational science and molecular design has enabled us to develop potentially first-in-class therapies that address significant unmet medical needs," said Dr. Xiaolin Zhang. "The selection of our data for presentation at ASCO underscores the scientific community's recognition of our innovative approach."
Dizal (搜索) continues to advance its pipeline of differentiated therapeutics for cancer and immunological diseases, with a commitment to developing groundbreaking new medicines that address unmet medical needs worldwide.
About Dizal
Dizal (搜索) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. Deep-rooted in translational science and molecular design, the company aims to develop first-in-class and groundbreaking new medicines to address unmet medical needs globally.
The ASCO Annual Meeting represents one of the world's largest gatherings of oncology professionals, providing a platform for presenting the latest advances in cancer research and treatment. Dizal (搜索)'s participation highlights the company's growing contribution to innovative cancer therapies and its commitment to addressing critical gaps in current treatment options.